The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

British Journal of Haematology (2013) - Comments
pubmed: 23360303 doi: 10.1111/bjh.12206 issn: 1365-2141 issn: 0007-1048

Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg, Steven Grant